Your search returned 3 results. Subscribe to this search

|
1. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors

by Barac, Ana.

Published: ; ; 2019Citation: Breast Cancer Research & Treatment. 174(3):785-794, 2019 Apr..Institution: MedStar Heart & Vascular Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Xu X; Chlebowski RT; Shi J; Barac A; Haque R.UI/PMID: 30659431.Digital Object Identifier: https://dx.doi.org/10.1007/s10549-018-05086-8 (Click here)
2. Cardiovascular Disease After Aromatase Inhibitor Use

by Barac, Ana.

Published: 2016Citation: JAMA Oncology. 2(12):1590-1597, 2016 Dec 01.Institution: MedStar Heart & Vascular Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Haque R; Shi J; Schottinger JE; Chung J; Avila C; Amundsen B; Xu X; Barac A; Chlebowski RT.UI/PMID: 27100398.Digital Object Identifier: https://dx.doi.org/10.1001/jamaoncol.2016.0429 (Click here)
3. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24

by Swain, Sandra M.

Citation: Journal of Clinical Oncology. 30(12):1268-73, 2012 Apr 20..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't.Full author list: Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE Jr; Costantino JP; Land SR; Wolmark N.UI/PMID: 22393101.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1200/JCO.2010.34.0141 (Click here)

Powered by Koha